Corcept Therapeutics Unusual Options Activity For April 01

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CORT, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 15 uncommon options trades for Corcept Therapeutics.

This isn't normal.

The overall sentiment of these big-money traders is split between 13% bullish and 73%, bearish.

Out of all of the special options we uncovered, 11 are puts, for a total amount of $599,257, and 4 are calls, for a total amount of $1,067,250.

Predicted Price Range

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $115.0 for Corcept Therapeutics, spanning the last three months.

Volume & Open Interest Trends

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Corcept Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Corcept Therapeutics's substantial trades, within a strike price spectrum from $65.0 to $115.0 over the preceding 30 days.

Corcept Therapeutics 30-Day Option Volume & Interest Snapshot

Noteworthy Options Activity:

About Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Following our analysis of the options activities associated with Corcept Therapeutics, we pivot to a closer look at the company's own performance.

Current Position of Corcept Therapeutics

• With a trading volume of 3,215,057, the price of CORT is up by 0.53%, reaching $114.82.
• Current RSI values indicate that the stock is may be overbought.
• Next earnings report is scheduled for 29 days from now.

What Analysts Are Saying About Corcept Therapeutics

In the last month, 3 experts released ratings on this stock with an average target price of $147.33.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Canaccord Genuity persists with their Buy rating on Corcept Therapeutics, maintaining a target price of $142. * An analyst from HC Wainwright & Co. persists with their Buy rating on Corcept Therapeutics, maintaining a target price of $150. * Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $150.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Corcept Therapeutics with Benzinga Pro for real-time alerts.